In memoriam

Beata Majkowska-Zwolińska/ Joanna Jędrzejczak

DOI: 10.21307/jepil-2019-007

Recommendations of the Polish Society of Epileptology for the treatment of epileptic seizure in adult patients in Poland: an update

Joanna Jędrzejczak/ Beata Majkowska-Zwolińska/ Danuta Ryglewicz/ Ewa Nagańska/ Maria Mazurkiewicz-Bełdzińska

Introduction. Introduction. In 2014, a group of Polish epilepsy experts published recommendations for antiepileptic drug (AED) use in adults with epilepsy. Selection of AEDs was based on the registration and reimbursement status in Poland, evidence of efficacy, and the personal views and experiences of the epilepsy practitioners. Method. Method. In 2018 previous recommendations were reviewed by the ad hoc group consisting of the authors of the original paper and additional epilepsy experts. As a(..)

DOI: 10.21307/jepil-2019-002

Published Online: 27-March-2019

The influence of clinical and immune variables on psychopathological syndromes in partial epilepsies in relation to handedness

Vladimir V. Kalinin/ Elena V. Zheleznova/ Kirill Y. Subbotin/ Natalia G. Yermakova/ Anna A. Zemlyanaya/ Lyudmila V. Sokolova

Background. Background. The role of neurobiological and immunity variables in the genesis of psychopathological syndromes in patients with partial epilepsy is not properly understood. It concerns also the role of handedness. Aim. Aim. The study was carried out in order to find the influence of clinical (neurobiological) and immune variables on co-morbid psychopathological syndromes in patients with epilepsy separately for right-handers and left-handers. Material and Methods. Material and Methods(..)

DOI: 10.21307/jepil-2019-005

Published Online: 12-September-2019

Rational polytherapy: Myth or reality?

José Pimentel/ José Manuel Lopes Lima

Background. Background. The concept of rational polytherapy implies using a combination of antiepileptic drugs with synergistic effect, which in turn, may result in additive or reduced toxicity. This concept is not consensually accepted. Aim. Aim. To present evidence in favour and against rational polytherapy. Methods. Methods. Narrative literature review on PubMed and Medline databases using the following terms: epilepsy treatment, rational therapy/polytherapy, supraadditive treatment, drug-res(..)

DOI: 10.21307/jepil-2019-003

Published Online: 02-July-2019

Cannabinoids in the treatment of epilepsy – an updated review

Marcin Kopka

Introduction. Introduction. It is estimated that 30% of people with epilepsy continue to have seizures despite treatment. The approval of many new antiseizure drugs during the past two decades has not substantially reduced the proportion of patients with medically refractory disease. Patients need new treatments. Many families choose to try alternative therapy options. An abundance of preclinical evidence and anecdotal human data support the use of cannabinoids in the treatment of epilepsy. Aim.(..)

DOI: 10.21307/jepil-2019-004

Published Online: 05-September-2019

Ictal asystole with reduced cardiac sympathetic function in new-onset symptomatic epilepsy

Julia Matzen/ Friedhelm C. Schmitt/ Michael C. Kreissl/ Jürgen Voges/ Hans-Jochen Heinze/ Imke Galazky

Introduction. Introduction. So far, cardiac sympathetic dysfunction, demonstrated in pharmacoresistant epilepsy patients with ictal bradycardia or asystole by I-123 metaiodobenzylguanidine (I-123 MIBG) imaging has been attributed to repeated occurrence of seizure activity. Aim. Aim. Discussion of the mechanisms of cardiac sympathetic dysfunction associated with ictal asystole under consideration of a case with new onset epilepsy. Materials and methods. Materials and methods. We describe the occu(..)

DOI: 10.21307/jepil-2019-001

Published Online: 16-February-2019

Glucose transporter type 1 deficiency syndrome (GLUT1-DS) – delayed diagnosis and treatment. A case report

Piotr Bogucki/ Ewa Nagańska/ Marta Jurek/ Dorota Hoffman-Zacharska/ Anna Kutkowska-Kaźmierczak/ Ewa Obersztyn/ Urszula Fiszer

Background. Background. Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is a treatable metabolic disorder caused by mutation in the SLC2A1 gene. The functional deficiency of the GLUT1 protein leads to impaired glucose transport into the brain, resulting in a spectrum of neurological phenotypes. The most severe classic phenotype comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor coordination disturbances, and spasticity. (..)

DOI: 10.21307/jepil-2019-006

Published Online: 21-November-2019